Scrip's Guide To Spinal Muscular Atrophy Therapies
INFOGRAPHIC: The prospects for patients with spinal muscular atrophy, the leading cause of genetic death in infants, have been revolutionized by the arrival of the first approved drug for the disease, Biogen’s blockbuster Spinraza. Now, other firms with equally revolutionary product candidates are giving chase. Scrip takes a look at the main contenders.
You may also be interested in...
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.
Novartis and Roche have announced additional interim clinical data as their candidate spinal muscular atrophy therapies near the marketplace.
The firm’s potential new therapy for the negative symptoms of schizophrenia is now in the hands of the US Food and Drug Administration – some have concerns over whether the supporting data will be enough.